0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Clinical Implications of Basic Neuroscience Research |

Cellular Prion Protein Mediates the Toxicity of β-Amyloid Oligomers Implications for Alzheimer Disease FREE

Haakon B. Nygaard, MD; Stephen M. Strittmatter, MD, PhD
[+] Author Affiliations

Author Affiliations:Program in Cellular Neuroscience, Neurodegeneration and Repair, Yale University School of Medicine, New Haven, Connecticut.


Section Editor: Hassan M. Fathallah-shaykh, MD, PhD

More Author Information
Arch Neurol. 2009;66(11):1325-1328. doi:10.1001/archneurol.2009.223.
Text Size: A A A
Published online

Alzheimer disease (AD) is the most common cause of age-related dementia, affecting more than 25 million people worldwide. The accumulation of insoluble β-amyloid (Aβ) plaques in the brain has long been considered central to the pathogenesis of AD. However, recent evidence suggests that soluble oligomeric assemblies of Aβ may be of greater importance. β-Amyloid oligomers have been found to be potent synaptotoxins, but the mechanism by which they exert their action has remained elusive. Herein, we review the recently published finding that cellular prion protein (PrPc) is a high-affinity receptor for Aβ oligomers, mediating their toxic effects on synaptic plasticity. We further discuss the relationship between AD and PrPcand the potential clinical implications. Cellular prion protein may provide a novel target for therapeutic intervention in AD.

Figures in this Article

Alzheimer disease (AD) is a debilitating neurodegenerative disorder, estimated to affect at least 26.6 million people worldwide.1Over the next 40 years, this number is predicted to increase 4-fold,1stressing the need for more effective therapeutics. For many years, the leading hypothesis for the pathogenesis of AD has involved the toxic effects of a gradual buildup of β-amyloid (Aβ) plaques in the brain.2β-Amyloid is produced after sequential processing of the amyloid precursor protein (APP),2and increased levels of the Aβ1-42species are thought to be a key early event in AD.3A major criticism of the amyloid hypothesis has been that the burden of fibrillar Aβ, the insoluble species constituting plaques, correlates poorly with the degree of dementia4and brain atrophy,5and cognitively normal individuals may have significant plaque deposition at autopsy.6However, more recent findings have elucidated different assemblies of Aβ with varying degrees of toxic effects. β-Amyloid can exist as soluble monomers and oligomers, intermediate protofibrils, and insoluble fibrillar aggregates.7Of these, soluble Aβ oligomers are potent synaptotoxins,8and their concentration correlates with disease severity.9

Oligomers are small peptide polymers, and various toxic Aβ oligomers have been reported, ranging from dimers and trimers10to 100mers.11Nanomolar concentrations of Aβ oligomers strongly inhibit long-term potentiation (LTP),12,13a leading experimental model for the synaptic changes underlying learning and memory. Recent evidence also suggests that synapse degeneration, likely central to the memory impairment in AD,14first involves the single synaptic contact points between axons and dendrites found at dendritic spines.15Consistent with their role in neurodegeneration, Aβ oligomers cause significant decrease in dendritic spine density in cultured hippocampal neurons.15Behavioral assessments in rodents have confirmed these findings, complementing a growing number of in vitro investigations. β-Amyloid oligomers greatly impair spatial memory when administered to otherwise healthy rats.12,16

The concept of oligomeric Aβ synaptotoxins has helped strengthen the amyloid hypothesis. In transgenic mice, levels of specific Aβ oligomers closely match deficits in spatial memory,16and clinically the amount of soluble Aβ in the brain correlates well with the degree of dementia.9Moreover, Aβ oligomers isolated directly from human AD brains have been found to be equally toxic as synthetically derived Aβ.17Despite these recent breakthroughs, the mechanisms by which Aβ oligomers exert their action have not been well understood. The effects on neurons are rapid and specific, and together the accumulated data have suggested the presence of a high-affinity Aβ oligomer receptor. This putative receptor would likely be central to the pathogenesis of AD and provide an attractive target for therapeutic intervention. Herein, we review the recent finding that cellular prion protein (PrPc) is a high-affinity binding site for Aβ oligomers, mediating their potent inhibitory effects on synaptic plasticity.11We further discuss the association between PrPcand AD and the potential clinical relevance of these findings.

To detect Aβ oligomer binding sites, a biotin-tagged Aβ1-42peptide was first synthesized.11Biotin is frequently used as a molecular marker because of its extraordinarily high affinity for the protein avidin that, in turn, can be used for detection. The Aβ was oligomerized and applied to COS-7 cells expressing different complementary DNA (cDNA) obtained from an adult mouse brain library. At baseline, COS-7 cells show minimal binding of Aβ oligomers compared with hippocampal neurons, making these cells ideal for this type of screen. Biotin-Aβ oligomers potently bind hippocampal neurons, whereas monomeric Aβ does not, suggesting a necessary conformation of Aβ conferred by oligomerization.

Of 225 000 clones from the adult mouse cDNA library screened in the assay, 2 were found to bind biotin-Aβ oligomers. Both of these individual clones were subsequently shown to encode for full-length mouse PrPc. In addition to this unbiased genome-wide screen, a more specific library of known transmembrane proteins at lower stringency was assessed. As summarized in the Table, some were found to exhibit Aβ oligomer binding but with lesser affinity and selectivity than for PrPc. Several putative receptors for Aβ have previously been reported, including the receptor for advanced glycation end products,18α7 nicotinic acetylcholine receptor,19and tumor necrosis factor receptor 1.20In the binding assay reviewed herein, only PrPchad high affinity and high specificity for Aβ oligomers.

Table Graphic Jump LocationTable. β-Amyloid (Aβ) Oligomer Protein Binding

Cellular prion protein is a glycosylphosphatidylinositol-linked extracellular membrane protein of approximately 250 amino acids that is abundantly expressed in the nervous system.21It is likely best known to clinicians because of its role in human prion disease. Using PrPcdeletion mutants, the exact binding site of Aβ oligomers was mapped to the region of amino acids 95 to 110. This area is within the unstructured central domain of PrPc(amino acids 95-134), which has been implicated in neuronal toxic effects in vitro22and in extensive neurodegeneration in mice.23α-Secretase, which cleaves APP within the Aβ domain (precluding the toxic Aβ peptide), also cleaves PrPcwithin its unstructured central domain at amino acids 110 to 111.24Therefore, α-secretase may act to counter neurodegeneration by preventing the production of Aβ and by keeping potentially detrimental regions of PrPcin check. It is unknown whether cleavage of PrPcby α-secretase also affects Aβ oligomer binding.

To evaluate the functional role of the Aβ oligomer–×-PrPcinteraction, the effects of Aβ oligomers on LTP were measured in brain sections from mice in which the PrPcgene was knocked out (PRNP/−) (176640). In wild-type hippocampal sections, a brief train of pulses in the theta frequency to Schaffer collateral fibers results in an increase in the excitatory postsynaptic potentials that can last for hours. This change in synaptic strength in response to a specific stimulus is believed to be a fundamental mechanism underlying learning and memory. When nanomolar concentrations of Aβ oligomers were applied to wild-type sections, LTP was strongly inhibited, as has been reported by numerous laboratories.10,13,17,20In contrast, no inhibitory effects on LTP were seen when the same Aβ preparation was applied to brain sections from PRNP/− animals, suggesting that Aβ oligomer signaling is mediated through PrPc.11To confirm these findings, wild-type brain sections were pretreated with 6D11, a specific antibody to PrPcfound to block Aβ oligomer binding. When these pretreated sections were exposed to the Aβ solution, LTP was unaffected, further suggesting a critical role of PrPcin Aβ oligomer–induced synaptotoxic effects.

Because PrPcis an extracellular protein, downstream Aβ oligomer signaling is likely mediated via a putative PrPc-associated transmembrane coreceptor (Figure). This putative coreceptor may have a critical role in AD-related neurodegeneration and, once identified, could provide an additional potential therapeutic target.

Place holder to copy figure label and caption
Figure.

β-Amyloid (Aβ) oligomer signaling. The amyloid precursor protein (APP) is cleaved by β-secretase and γ-secretase to produce monomeric Aβ peptides that, in turn, assemble into toxic Aβ oligomers. β-Amyloid oligomers bind to cellular prion protein (PrPc), which likely signals via a putative transmembrane PrPccoreceptor. This binding mediates the inhibition of synaptic plasticity as measured by long-term potentiation and could be involved in other deleterious effects of Aβ oligomers, including synapse degeneration, rodent spatial memory impairments, and the neurodegeneration seen in human Alzheimer disease. Long-term potentiation may be suppressed by altering neurotransmission through N-methyl-D-aspartate receptors (NMDARs) and α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) receptors (AMPARs), as their distribution has been shown to be regulated by Aβ oligomers.

Graphic Jump Location

For at least a decade, an indirect association between AD and PrPchas been lingering in the literature. Early interest was fueled mostly by the fact that AD and human prion disease involve aggregates of pathologic proteins in the brain25and that the amyloid precursor–like protein was reported to bind PrPc.26Recently, more specific evidence has emerged linking PrPcto AD. From a genetic perspective, interest has been growing in the PRNPmethionine/valine polymorphism (M129V) and its relationship to sporadic AD. Homozygosity at this codon, which is located within the unstructured central domain of PrPc, is associated with an increased risk of sporadic Creutzfeldt-Jakob disease.27Others have found that this genotype confers an increased risk for sporadic AD in certain populations.28Whether polymorphisms within the PRNPgene may affect Aβ oligomer binding to PrPcand alter susceptibility to AD is unknown, but it remains an intriguing possibility.

Cellular prion protein has also been reported to regulate APP processing by modulating β-secretase (BACE1) activity, but the results have been conflicting. Cells coexpressing APP and PrPchave a significant reduction in secreted Aβ compared with cells expressing APP alone.29The region of PrPcresponsible for this action was found to be in the N-terminus (amino acids 23-26), as no effects on BACE1 or Aβ levels were seen when this segment was removed.29However, overexpressing PrPcin transgenic APP mice caused a modest increase of Aβ plaques in the brain,30in contrast to the lowering effect of PrPcfound in vitro. It is unclear whether binding of Aβ oligomers to PrPcmight affect its proposed ability to regulate BACE1, setting up a potential feedback loop in response to Aβ levels, and this is an issue worth investigating further as the field moves forward.

In summary, we have reviewed the recent finding that PrPcfunctions as a high-affinity receptor to mediate the deleterious effects of Aβ oligomers on synaptic plasticity. Although much work remains to assess whether targeting PrPcor its putative coreceptor can be effective treatments in human AD, the potential is readily apparent. Cellular prior protein represents the first possible target in AD directly disrupting the signaling pathway of Aβ and might provide a more functional approach to relieving AD symptoms. Most important, modulating PrPcfunction does not seem to produce serious adverse effects, as PRNPknockout mice have minimal phenotypic changes and wild-type animals treated with PrPcantibodies do well. A large body of work on PrPcalready exists because of its role in prion diseases. This knowledge could greatly facilitate drug discovery and our understanding of the downstream mechanisms of the Aβ oligomer–×-PrPcinteraction.

Correspondence:Stephen M. Strittmatter, MD, PhD, Program in Cellular Neuroscience, Neurodegeneration and Repair, Yale University School of Medicine, 295 Congress Ave, Boyer Center for Molecular Medicine 436, New Haven, CT 06536-0812 (stephen.strittmatter@yale.edu).

Accepted for Publication:May 13, 2009.

Author Contributions:Study concept and design: Nygaard and Strittmatter. Acquisition of data: Nygaard and Strittmatter. Analysis and interpretation of data: Nygaard and Strittmatter. Drafting of the manuscript: Nygaard and Strittmatter. Critical revision of the manuscript for important intellectual content: Nygaard and Strittmatter. Obtained funding: Strittmatter. Administrative, technical, and material support: Strittmatter. Study supervision: Strittmatter.

Financial Disclosure:None reported.

Funding/Support:This study was supported by grants from the Cure Alzheimer's Fund, National Institutes of Health, and Falk Medical Research Trust (Dr Strittmatter).

Brookmeyer  RJohnson  EZiegler-Graham  KArrighi  HM Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007;3 (3) 186- 191
PubMed Link to Article
Hardy  JSelkoe  DJ The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics [published correction appears in Science. 2002;297(5590):2209]. Science 2002;297 (5580) 353- 356
PubMed Link to Article
Younkin  SG The role of Aβ42 in Alzheimer's disease. J Physiol Paris 1998;92 (3-4) 289- 292
PubMed Link to Article
Terry  RDMasliah  ESalmon  DP  et al.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30 (4) 572- 580
PubMed Link to Article
Josephs  KAWhitwell  JLAhmed  Z  et al.  β-Amyloid burden is not associated with rates of brain atrophy. Ann Neurol 2008;63 (2) 204- 212
PubMed Link to Article
Katzman  RTerry  RDeTeresa  R  et al.  Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 1988;23 (2) 138- 144
PubMed Link to Article
Klein  WL Aβ toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 2002;41 (5) 345- 352
PubMed Link to Article
Lambert  MPBarlow  AKChromy  BA  et al.  Diffusible, nonfibrillar ligands derived from Aβ1–42are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998;95 (11) 6448- 6453
PubMed Link to Article
McLean  CACherny  RAFraser  FW  et al.  Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999;46 (6) 860- 866
PubMed Link to Article
Townsend  MShankar  GMMehta  TWalsh  DMSelkoe  DJ Effects of secreted oligomers of amyloid β-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 2006;572 (pt 2) 477- 492
PubMed Link to Article
Laurén  JGimbel  DANygaard  HBGilbert  JWStrittmatter  SM Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. Nature 2009;457 (7233) 1128- 1132
PubMed Link to Article
Walsh  DMKlyubin  IFadeeva  JV  et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416 (6880) 535- 539
PubMed Link to Article
Wang  HWPasternak  JFKuo  H  et al.  Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 2002;924 (2) 133- 140
PubMed Link to Article
Selkoe  DJ Alzheimer's disease is a synaptic failure. Science 2002;298 (5594) 789- 791
PubMed Link to Article
Lacor  PNBuniel  MCFurlow  PW  et al.  Aβ oligomer–induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007;27 (4) 796- 807
PubMed Link to Article
Lesné  SKoh  MTKotilinek  L  et al.  A specific amyloid-β protein assembly in the brain impairs memory. Nature 2006;440 (7082) 352- 357
PubMed Link to Article
Shankar  GMLi  SMehta  TH  et al.  Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008;14 (8) 837- 842
PubMed Link to Article
Yan  SDChen  XFu  J  et al.  RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 1996;382 (6593) 685- 691
PubMed Link to Article
Wang  HYLee  DHD’Andrea  MRPeterson  PAShank  RPReitz  AB β-Amyloid1-42binds to α7 nicotinic acetylcholine receptor with high affinity: implications for Alzheimer's disease pathology. J Biol Chem 2000;275 (8) 5626- 5632
PubMed Link to Article
Wang  QWu  JRowan  MJAnwyl  R β-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. Eur J Neurosci 2005;22 (11) 2827- 2832
PubMed Link to Article
Aguzzi  ABaumann  FBremer  J The prion's elusive reason for being. Annu Rev Neurosci 2008;31439- 477
PubMed Link to Article
Forloni  GAngeretti  NChiesa  R  et al.  Neurotoxicity of a prion protein fragment. Nature 1993;362 (6420) 543- 546
PubMed Link to Article
Baumann  FTolnay  MBrabeck  C  et al.  Lethal recessive myelin toxicity of prion protein lacking its central domain. EMBO J 2007;26 (2) 538- 547
PubMed Link to Article
Vincent  BCisse  MASunyach  CGuillot-Sestier  MVChecler  F Regulation of βAPP and PrPc cleavage by α-secretase: mechanistic and therapeutic perspectives. Curr Alzheimer Res 2008;5 (2) 202- 211
PubMed Link to Article
Aguzzi  AHaass  C Games played by rogue proteins in prion disorders and Alzheimer's disease. Science 2003;302 (5646) 814- 818
PubMed Link to Article
Yehiely  FBamborough  PDa Costa  M  et al.  Identification of candidate proteins binding to prion protein [published correction appears in Neurobiol Dis. 2002;10(1):67-68]. Neurobiol Dis 1997;3 (4) 339- 355
PubMed Link to Article
Palmer  MSDryden  AJHughes  JTCollinge  J Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease [published correction appears in Nature. 1991;352(6335):547]. Nature 1991;352 (6333) 340- 342
PubMed Link to Article
Del Bo  RScarlato  MGhezzi  S  et al.  Is M129V of PRNP gene associated with Alzheimer's disease?  a case-control study and a meta-analysis. Neurobiol Aging. 2006;27 ((5)) 770.e1- 770.e5.http://www.journals.elsevierhealth.com/periodicals/nba/article/PIIS0187458005001612/abstract. Accessed May 1, 2009
Link to Article
Parkin  ETWatt  NTHussain  I  et al.  Cellular prion protein regulates β-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc Natl Acad Sci U S A 2007;104 (26) 11062- 11067
PubMed Link to Article
Schwarze-Eicker  KKeyvani  KGörtz  NWestaway  DSachser  NPaulus  W Prion protein (PrPc) promotes β-amyloid plaque formation. Neurobiol Aging 2005;26 (8) 1177- 1182
PubMed Link to Article

Figures

Place holder to copy figure label and caption
Figure.

β-Amyloid (Aβ) oligomer signaling. The amyloid precursor protein (APP) is cleaved by β-secretase and γ-secretase to produce monomeric Aβ peptides that, in turn, assemble into toxic Aβ oligomers. β-Amyloid oligomers bind to cellular prion protein (PrPc), which likely signals via a putative transmembrane PrPccoreceptor. This binding mediates the inhibition of synaptic plasticity as measured by long-term potentiation and could be involved in other deleterious effects of Aβ oligomers, including synapse degeneration, rodent spatial memory impairments, and the neurodegeneration seen in human Alzheimer disease. Long-term potentiation may be suppressed by altering neurotransmission through N-methyl-D-aspartate receptors (NMDARs) and α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) receptors (AMPARs), as their distribution has been shown to be regulated by Aβ oligomers.

Graphic Jump Location

Tables

Table Graphic Jump LocationTable. β-Amyloid (Aβ) Oligomer Protein Binding

References

Brookmeyer  RJohnson  EZiegler-Graham  KArrighi  HM Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007;3 (3) 186- 191
PubMed Link to Article
Hardy  JSelkoe  DJ The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics [published correction appears in Science. 2002;297(5590):2209]. Science 2002;297 (5580) 353- 356
PubMed Link to Article
Younkin  SG The role of Aβ42 in Alzheimer's disease. J Physiol Paris 1998;92 (3-4) 289- 292
PubMed Link to Article
Terry  RDMasliah  ESalmon  DP  et al.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30 (4) 572- 580
PubMed Link to Article
Josephs  KAWhitwell  JLAhmed  Z  et al.  β-Amyloid burden is not associated with rates of brain atrophy. Ann Neurol 2008;63 (2) 204- 212
PubMed Link to Article
Katzman  RTerry  RDeTeresa  R  et al.  Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 1988;23 (2) 138- 144
PubMed Link to Article
Klein  WL Aβ toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 2002;41 (5) 345- 352
PubMed Link to Article
Lambert  MPBarlow  AKChromy  BA  et al.  Diffusible, nonfibrillar ligands derived from Aβ1–42are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998;95 (11) 6448- 6453
PubMed Link to Article
McLean  CACherny  RAFraser  FW  et al.  Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999;46 (6) 860- 866
PubMed Link to Article
Townsend  MShankar  GMMehta  TWalsh  DMSelkoe  DJ Effects of secreted oligomers of amyloid β-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 2006;572 (pt 2) 477- 492
PubMed Link to Article
Laurén  JGimbel  DANygaard  HBGilbert  JWStrittmatter  SM Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. Nature 2009;457 (7233) 1128- 1132
PubMed Link to Article
Walsh  DMKlyubin  IFadeeva  JV  et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416 (6880) 535- 539
PubMed Link to Article
Wang  HWPasternak  JFKuo  H  et al.  Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 2002;924 (2) 133- 140
PubMed Link to Article
Selkoe  DJ Alzheimer's disease is a synaptic failure. Science 2002;298 (5594) 789- 791
PubMed Link to Article
Lacor  PNBuniel  MCFurlow  PW  et al.  Aβ oligomer–induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007;27 (4) 796- 807
PubMed Link to Article
Lesné  SKoh  MTKotilinek  L  et al.  A specific amyloid-β protein assembly in the brain impairs memory. Nature 2006;440 (7082) 352- 357
PubMed Link to Article
Shankar  GMLi  SMehta  TH  et al.  Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008;14 (8) 837- 842
PubMed Link to Article
Yan  SDChen  XFu  J  et al.  RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 1996;382 (6593) 685- 691
PubMed Link to Article
Wang  HYLee  DHD’Andrea  MRPeterson  PAShank  RPReitz  AB β-Amyloid1-42binds to α7 nicotinic acetylcholine receptor with high affinity: implications for Alzheimer's disease pathology. J Biol Chem 2000;275 (8) 5626- 5632
PubMed Link to Article
Wang  QWu  JRowan  MJAnwyl  R β-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. Eur J Neurosci 2005;22 (11) 2827- 2832
PubMed Link to Article
Aguzzi  ABaumann  FBremer  J The prion's elusive reason for being. Annu Rev Neurosci 2008;31439- 477
PubMed Link to Article
Forloni  GAngeretti  NChiesa  R  et al.  Neurotoxicity of a prion protein fragment. Nature 1993;362 (6420) 543- 546
PubMed Link to Article
Baumann  FTolnay  MBrabeck  C  et al.  Lethal recessive myelin toxicity of prion protein lacking its central domain. EMBO J 2007;26 (2) 538- 547
PubMed Link to Article
Vincent  BCisse  MASunyach  CGuillot-Sestier  MVChecler  F Regulation of βAPP and PrPc cleavage by α-secretase: mechanistic and therapeutic perspectives. Curr Alzheimer Res 2008;5 (2) 202- 211
PubMed Link to Article
Aguzzi  AHaass  C Games played by rogue proteins in prion disorders and Alzheimer's disease. Science 2003;302 (5646) 814- 818
PubMed Link to Article
Yehiely  FBamborough  PDa Costa  M  et al.  Identification of candidate proteins binding to prion protein [published correction appears in Neurobiol Dis. 2002;10(1):67-68]. Neurobiol Dis 1997;3 (4) 339- 355
PubMed Link to Article
Palmer  MSDryden  AJHughes  JTCollinge  J Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease [published correction appears in Nature. 1991;352(6335):547]. Nature 1991;352 (6333) 340- 342
PubMed Link to Article
Del Bo  RScarlato  MGhezzi  S  et al.  Is M129V of PRNP gene associated with Alzheimer's disease?  a case-control study and a meta-analysis. Neurobiol Aging. 2006;27 ((5)) 770.e1- 770.e5.http://www.journals.elsevierhealth.com/periodicals/nba/article/PIIS0187458005001612/abstract. Accessed May 1, 2009
Link to Article
Parkin  ETWatt  NTHussain  I  et al.  Cellular prion protein regulates β-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc Natl Acad Sci U S A 2007;104 (26) 11062- 11067
PubMed Link to Article
Schwarze-Eicker  KKeyvani  KGörtz  NWestaway  DSachser  NPaulus  W Prion protein (PrPc) promotes β-amyloid plaque formation. Neurobiol Aging 2005;26 (8) 1177- 1182
PubMed Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

1,240 Views
39 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
Jobs